[go: up one dir, main page]

JPH0975076A - Filter device for selecting and removing monocyte and/or macrophage derived from monocyte - Google Patents

Filter device for selecting and removing monocyte and/or macrophage derived from monocyte

Info

Publication number
JPH0975076A
JPH0975076A JP7257201A JP25720195A JPH0975076A JP H0975076 A JPH0975076 A JP H0975076A JP 7257201 A JP7257201 A JP 7257201A JP 25720195 A JP25720195 A JP 25720195A JP H0975076 A JPH0975076 A JP H0975076A
Authority
JP
Japan
Prior art keywords
monocyte
filter
cell
monocytes
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP7257201A
Other languages
Japanese (ja)
Other versions
JP3812909B2 (en
Inventor
Hirokazu Onodera
博和 小野寺
Jiyunsuke Suemitsu
淳輔 末光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Medical Co Ltd
Original Assignee
Asahi Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Medical Co Ltd filed Critical Asahi Medical Co Ltd
Priority to JP25720195A priority Critical patent/JP3812909B2/en
Publication of JPH0975076A publication Critical patent/JPH0975076A/en
Application granted granted Critical
Publication of JP3812909B2 publication Critical patent/JP3812909B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a filter device filled with a porous filter having a specific average pore cross section in a vessel having an inlet and an outlet and selectively removing monocyte and macrophage in a cell-floating solution, and useful for marrow transplantation and blood transfusion, etc. SOLUTION: This filter device is useful for transplantation of a peripheral vascular cell, marrow transplantation, blood transfusion and removing of monocyte from blood of a patient having inflammatory disease, etc., with a very simple operation. Monocyte and/or macrophage derived from monocyte in a cell-floating solution can selectively be removed by winding a sheet of non-woven cloth, etc., made of polyethylene terephthalate, etc., having 10-20μm average fiber diameter in a hollow cylindrical shape having 1.8cm thickness of a filter part to obtain a porous filter having 100-500μm<2> average pore cross section, filling the resultant filters in a hollow vessel having an inlet and an outlet of a liquid at both ends at a bulk density of 0.05-0.5g/cm<3> and fixing the filters by providing a mesh-type supporter at the most inner peripheral part and the most outer peripheral part.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、血液等の単球及び/又
は単球由来のマクロファージを含有する血球浮遊液から
単球及び/又は単球由来のマクロファージのみを選択的
に除去するための装置に関する。
TECHNICAL FIELD The present invention is for selectively removing only monocytes and / or monocyte-derived macrophages from a blood cell suspension containing monocytes such as blood and / or monocyte-derived macrophages. Regarding the device.

【0002】[0002]

【従来の技術】近年、モノクローナル抗体を用いた細胞
分離技術が発達し、免疫学、細胞生物学、血液学の分野
で広範囲に用いられている。即ち、細胞分離技術を用い
て血液等の細胞浮遊液から目的細胞のみを分離採取し、
活性化、増殖等種々の操作を施した後、患者に輸注する
等の操作が行われるようになった。この一例として、自
家骨髄移植における造血幹細胞及び/又は造血前駆細胞
の選択採取が挙げられる。自家骨髄移植は、大量の抗癌
剤及び/又は放射線療法の副作用である骨髄荒廃による
致死的造血障害を、前もって患者本人から採取し凍結保
存しておいた骨髄液等から採取した造血幹細胞を再輸注
することで回避する治療方法である。ところが、癌患者
の骨髄には癌細胞が浸潤している場合があり、これを再
輸注することで癌が再発してしまう可能性がある。ま
た、他人の骨髄や末梢血を移植するいわゆる同種骨髄移
植や同種末梢血移植の場合も、移植片対宿主病(GVH
D)等の重い副作用を予防するために他の成分が混在し
ない造血幹細胞のみを移植することが重要な課題となっ
てきた。
2. Description of the Related Art In recent years, cell separation technology using a monoclonal antibody has been developed and widely used in the fields of immunology, cell biology and hematology. That is, using a cell separation technique, only target cells are separated and collected from a cell suspension such as blood,
After performing various operations such as activation and proliferation, operations such as infusion into patients have come to be performed. An example of this is selective collection of hematopoietic stem cells and / or hematopoietic progenitor cells in autologous bone marrow transplantation. Autologous bone marrow transplantation reinjects hematopoietic stem cells collected from bone marrow fluid, etc., which had been collected from the patient and cryopreserved, for fatal hematopoietic disorders due to bone marrow depletion, which is a side effect of a large amount of anticancer agents and / or radiation therapy. This is a treatment method to avoid. However, cancer cells may be infiltrated into the bone marrow of a cancer patient, and the cancer may recur by reinfusion. In the case of so-called allogeneic bone marrow transplantation or allogeneic peripheral blood transplantation in which bone marrow or peripheral blood of another person is transplanted, graft-versus-host disease (GVH
In order to prevent serious side effects such as D), it has become an important issue to transplant only hematopoietic stem cells free from other components.

【0003】現在知られている造血幹細胞等の選択的採
取のための器具としては、抗体結合フラスコ、磁気ビー
ズ、アビジン−ビオチンカラム等がある(Hemato
poietic Stem Cell,Alpha M
ed Press,1994,186−187)。しか
し、これらは造血幹細胞/又は造血前駆細胞の回収率が
十分ではない。その原因として、血液等の浮遊液中の単
球の混在が指摘されている。この単球除去方法として、
単球の抗原であるCD14に対する抗体と磁気ビーズを
用いる方法も提案されているが、抗体を用いるためにコ
スト高である上、操作も繁雑である。更に、最近、自己
免疫性疾患や炎症性疾患患者の血液を体外に導き出して
白血球を除去した後、再び患者に戻すいわゆるロイコア
フェレーシスも盛んに行われるようになってきている。
現在のところ、白血球の全成分を高率に除去している
が、除去される白血球成分中にはリンパ球中のT細胞等
の有益な免疫細胞も含まれており、特に炎症性疾患にお
いては単球由来のマクロファージが炎症部位に遊走して
症状を悪化させることが知られており、単球のみを優先
的且つ選択的に除去することも望まれるところである。
しかし、これまで、血球浮遊液から細胞径の違いと白血
球の粘着性を利用して細孔直径が特定された繊維か又は
多孔質材からなるフィルターを用いて血球浮遊液から白
血球を捕捉する技術や、細孔直径の異なる2種のフィル
ターを段階的に用いて白血球の中のリンパ球だけを選択
的に分取する技術は既に知られているものの、単球だけ
を1回の処理で選択的に捕捉、除去するフィルター装置
は未だ知られていない。
Currently known instruments for selective collection of hematopoietic stem cells and the like include antibody-bound flasks, magnetic beads, avidin-biotin column and the like (Hemato).
poietic Stem Cell, Alpha M
ed Press, 1994, 186-187). However, these do not have a sufficient recovery rate of hematopoietic stem cells / or hematopoietic progenitor cells. As a cause for this, it has been pointed out that monocytes are mixed in a suspension such as blood. As this monocyte removal method,
A method using an antibody against CD14, which is a monocyte antigen, and magnetic beads has been proposed, but the cost is high and the operation is complicated because the antibody is used. Further, recently, so-called leukopheresis, which leads blood out of patients with autoimmune diseases and inflammatory diseases to the outside of the body to remove leukocytes, and then returns the blood to the patients again, has become popular.
At present, all components of white blood cells are removed at a high rate, but the white blood cell components to be removed include beneficial immune cells such as T cells in lymphocytes, and particularly in inflammatory diseases. It is known that monocyte-derived macrophages migrate to the site of inflammation and exacerbate the condition, and it is also desired to remove monocytes preferentially and selectively.
However, until now, a technique for capturing leukocytes from a hemocyte suspension by using a filter made of a fiber or a porous material whose pore diameter has been specified by utilizing the difference in cell diameter and adhesion of leukocytes from the hemocyte suspension. Although it is already known that two types of filters with different pore diameters are used in stages to selectively separate lymphocytes from white blood cells, only monocytes can be selected in a single treatment. A filter device for selectively capturing and removing is not yet known.

【0004】[0004]

【発明が解決しようとする課題】本発明は、単球及び/
又は単球由来のマクロファージを含有する血球浮遊液か
ら単球及び/又はマクロファージのみを選択的に除去す
るための、操作性に優れたフィルター装置を提供するこ
とを目的とする。白血球は大別して単球、顆粒球、リン
パ球からなるが、単球はこの中で最も平均直径が大き
い、即ち平均直径が約9〜12μmの細胞成分として知
られている。しかしながら顆粒球の平均直径が約7〜9
μm、又リンパ球が約5〜8μmとその差は微々たるも
のである上、個々の細胞によっては大きさが逆の場合も
少なくないため、単球を他の白血球成分と篩い分けの原
理のみで他の白血球成分と精度良く分離することは不可
能である。本発明者らが鋭意検討した結果、細胞成分が
通過する細孔部分の断面積が単球の断面積よりも若干大
きい細孔を有する特定の多孔質体を用いると意外なこと
に単球及び/又は単球由来のマクロファージのみが捕捉
され、顆粒球とリンパ球は細孔を通過することを見出
し、本発明を完成するに至った。即ち本発明は、平均細
孔断面積が100μm2 〜500μm2 である多孔質フ
ィルターを、液体の入口及び出口を有する容器に0.0
5g/cm3 〜0.5g/cm3 の嵩密度で充填したこ
とを特徴とする、細胞浮遊液中の単球及び/又は単球由
来のマクロファージ選択除去フィルター装置である。
SUMMARY OF THE INVENTION The present invention is directed to monocytes and / or
Another object of the present invention is to provide a filter device excellent in operability for selectively removing only monocytes and / or macrophages from a blood cell suspension containing monocyte-derived macrophages. White blood cells are roughly classified into monocytes, granulocytes, and lymphocytes, and monocytes are known as a cell component having the largest average diameter, that is, an average diameter of about 9 to 12 μm. However, the average diameter of granulocytes is about 7-9
μm, and the difference between lymphocytes is about 5 to 8 μm, which is insignificant, and in some cases the size may be reversed depending on the individual cell, so the principle of sieving monocytes from other leukocyte components is the only principle. Therefore, it is impossible to accurately separate it from other white blood cell components. As a result of diligent studies by the present inventors, the use of a specific porous body having a pore in which the cross-sectional area of the pore portion through which the cell component passes is slightly larger than the cross-sectional area of the monocyte is surprisingly It was found that only macrophages derived from / or monocytes were captured, and granulocytes and lymphocytes passed through pores, leading to completion of the present invention. The present invention provides a porous filter mean pore cross-sectional area is 100μm 2 ~500μm 2, in a container having an inlet and an outlet of the liquid 0.0
Characterized by being filled with bulk density of 5g / cm 3 ~0.5g / cm 3 , a macrophage selective removal filter apparatus of the monocyte-derived and / or monocyte cell suspension fluid.

【0005】本発明にいう細胞浮遊液とは、少なくとも
単球及び/又は単球由来のマクロファージを含む液をい
う。具体例としては、骨髄液、臍帯血又は抹消血、G−
CSF、GM−CSF等の造血因子を投与した抹消血、
全血或はこれらを比重遠心分離により得た単核球細胞浮
遊液或はバフィーコート等が挙げられる。本発明にいう
多孔質フィルターは、単球及び/又は単球由来のマクロ
ファージを含む細胞浮遊液と接触して生物学的作用であ
る食作用や、粘着や静電的、或は疎水的等の化学的相互
作用により単球及び/又は単球由来のマクロファージを
優先的に一部又は実質的に全部捕捉、除去する部材をい
う。本発明に用いられる多孔質フィルターとしては、不
織布、織布、綿布等繊維材料からなるものや、スポン
ジ、ゲル、多孔質膜等の多孔質体からなるものが挙げら
れる。この中でも比表面積が大きく、且つ多数の細孔を
有する不織布やスポンジ状の多孔質体が好適に用いられ
る。またその材質としては水不溶性であれば如何なる材
質も使用可能であるが、成形性や滅菌時の安定性、安全
性から好ましいものを例示すると、ポリエチレンテレフ
タレート、ポリブチレンテレフタレート等のポリエステ
ル、ナイロン6、ナイロン6,6等のポリアミド、ポリ
スチレン及びその誘導体、ポリビニルホルマール、ポリ
スルホン、ポリウレタン、ポリビニルアセタール、ポリ
カーボネート等の合成高分子化合物であり、これら化合
物の単量体の単独重合体、共重合体、ブロック重合体及
び上記高分子化合物のブレンド及びアロイ化したものを
含むものや、セルロース及び/又はその誘導体等の再生
繊維及び上述の合成高分子化合物とのブレンド、アロイ
化したものを含むもの等が挙げられる。
The cell suspension referred to in the present invention means a liquid containing at least monocytes and / or monocyte-derived macrophages. Specific examples include bone marrow fluid, cord blood or peripheral blood, G-
Peripheral blood administered with hematopoietic factors such as CSF and GM-CSF,
Examples include whole blood, a mononuclear cell suspension obtained by centrifuging these, or buffy coat. The porous filter referred to in the present invention has a biological effect such as phagocytosis, adhesion, electrostaticity, hydrophobicity or the like in contact with a cell suspension containing monocytes and / or monocyte-derived macrophages. A member that preferentially captures or removes monocytes and / or monocyte-derived macrophages partially or substantially entirely by chemical interaction. Examples of the porous filter used in the present invention include those made of fibrous materials such as non-woven fabric, woven fabric and cotton fabric, and those made of porous materials such as sponge, gel and porous membrane. Among them, a nonwoven fabric having a large specific surface area and having a large number of pores or a sponge-like porous body is preferably used. As the material, any material can be used as long as it is water-insoluble. However, preferable examples from the viewpoint of moldability, stability during sterilization, and safety are polyesters such as polyethylene terephthalate and polybutylene terephthalate, nylon 6, nylon 6, Synthetic polymer compounds such as polyamides such as nylon 6,6, polystyrene and its derivatives, polyvinyl formal, polysulfone, polyurethane, polyvinyl acetal, and polycarbonate, and homopolymers, copolymers, and block copolymers of monomers of these compounds. Examples thereof include coalesced products and blends of the above-mentioned polymer compounds and alloyed products, blends of regenerated fibers such as cellulose and / or derivatives thereof and the above-mentioned synthetic polymer compounds, and alloyed products. .

【0006】本発明にいう多孔質フィルターの平均細孔
断面積は、フィルターを血液の流れ方向に対して垂直方
向に切断したときその切断面に分散している個々の細孔
を円又は楕円とみなし、それらについて求めた面積の相
加平均値である。細孔の形状が円又は楕円とみなし得な
い場合、例えば細孔が直線状の繊維で囲まれた多角形に
近似している場合は、最も狭い孔幅部分と最も太い孔幅
部分の長さを相加平均して求まる値をその孔の細孔径と
して面積を算出する。平均細孔断面積は多孔質フィルタ
ーの表層からフィルターの厚み方向に対して0.5mm
以内の任意の深度部の切断面を走査型電子顕微鏡で撮影
し、目視により撮影面上に分散している細孔の直径又は
長径が1μm未満の細孔を除き、ランダムに100個以
上測定して求める。最も簡便且つ測定者の習熟度による
誤差が生じにくい測定手法として、電子顕微鏡を用いて
任意の切断面の細孔を撮影し、これを公知のコンピュー
タによる画像解析処理によって細孔部と細孔壁部とに色
調のコントラストをつけて細孔部を明確化して個々の細
孔部の面積を相加平均する方法が好ましく挙げられる。
上述の測定方法によって求められる本発明の多孔質フィ
ルターの平均細孔断面積は100μm2 〜500μm
2 、好ましくは100μm2 〜400μm2 である。
The average pore cross-sectional area of the porous filter according to the present invention means that when the filter is cut in the direction perpendicular to the blood flow direction, the individual pores dispersed on the cut surface are circles or ellipses. It is regarded as an arithmetic mean value of the areas obtained for them. If the shape of the pores cannot be regarded as a circle or an ellipse, for example, if the pores approximate a polygon surrounded by linear fibers, the length of the narrowest and widest pores The area is calculated using the value obtained by arithmetically averaging as the pore diameter of the pore. The average pore cross-sectional area is 0.5 mm from the surface of the porous filter to the thickness direction of the filter.
The cut surface at an arbitrary depth within the range is photographed with a scanning electron microscope, and 100 or more are randomly measured except for the pores whose diameter or major axis is less than 1 μm dispersed in the photographed surface by visual observation. Ask for. As the simplest and most easy measurement method in which errors due to the skill of the measurer do not occur, the pores on the arbitrary cut surface are photographed using an electron microscope, and the pores and pore walls are subjected to image analysis processing by a known computer. Preferable is a method of clarifying the fine pores by giving a contrast of color tone to the fine portions and arithmetically averaging the areas of the individual fine pores.
The average pore cross-sectional area of the porous filter of the present invention determined by the above measuring method is 100 μm 2 to 500 μm.
2, preferably 100μm 2 ~400μm 2.

【0007】本発明に用いられる多孔質フィルターは微
視的に見ると捕捉対象細胞である単球よりもやや大きめ
の細孔からなる。ところが意外なことに単球及び/又は
単球由来のマクロファージのみが選択的に捕捉され、他
のリンパ球や顆粒球は実質的に全く捕捉されないのであ
る。即ち単球及び/又は単球由来のマクロファージは細
孔のサイズよりも小さいので、従来の篩い分けの原理か
ら考えると細孔壁に接触しそこに引っ掛かったままにな
る機会が少なく、到底高率に捕捉されることは予想され
ないのであるが、本発明者等が検討した結果、本発明の
特徴を有する大きめの断面積を有する細孔が、単球及び
/又は単球由来のマクロファージがその食作用によって
フィルター壁を異物と認識してそこに吸着するのに適し
た大きさであることを突き止めたのである。多孔質フィ
ルターの平均細孔断面積が100μm2 未満では、単球
以外の細胞成分が捕捉される可能性がある。又平均細孔
断面積が500μm2 を越えると単球とフィルター壁と
の接触頻度が低下してしまうため単球の食作用がもはや
十分に発揮されなくなり、単球の捕捉率が著しく低下し
てしまう。
Microscopically, the porous filter used in the present invention is composed of pores slightly larger than monocytes, which are cells to be captured. Surprisingly, however, only monocytes and / or monocyte-derived macrophages are selectively captured, and other lymphocytes and granulocytes are substantially not captured. That is, since monocytes and / or monocyte-derived macrophages are smaller than the size of the pores, considering the principle of conventional sieving, there is little chance of coming into contact with the pore wall and remaining trapped there, and it is extremely high. However, as a result of examination by the present inventors, the pores having a large cross-sectional area having the features of the present invention show that monocytes and / or macrophages derived from monocytes have their phagocytosis. By the action, they identified the filter wall as a foreign substance and found that it had a size suitable for being adsorbed there. If the average pore cross-sectional area of the porous filter is less than 100 μm 2 , cell components other than monocytes may be captured. Further, when the average pore cross-sectional area exceeds 500 μm 2 , the frequency of contact between the monocytes and the filter wall is reduced, so that the phagocytosis of the monocytes is no longer sufficiently exerted, and the monocyte capture rate is significantly reduced. I will end up.

【0008】本発明に用いられる多孔質フィルターに
は、表面に親水性を付与することも好ましい。親水性を
付与することにより被処理細胞浮遊液に存在する他の細
胞の非特異吸着を防止するのに有効にはたらく。表面を
親水化する場合、血液等の細胞浮遊液中の蛋白質の吸着
を抑制する目的で水酸基を導入することも好ましい。又
非特異吸着を抑制するためにカチオン性基を導入するこ
とは静電的な作用が期待できるので好ましい。ここにい
うカチオン性基とは、アミン類及びアミン誘導体等が含
まれ、3級及び4級アミノ基が挙げられる。多孔質フィ
ルター表面への親水性付与は、各種官能基を共有結合、
イオン結合、疎水結合等で表面に結合させれば良い。結
合方法としては、放射線グラフト、コーティング等いず
れの方法を用いても良好である。親水性を付与するため
に導入する官能基の例を示すと、繰り返し単位が2から
100のポリエチレングリコール鎖、水酸基、アミド
基、エーテル基、エステル基等が挙げられる。親水性を
与えるポリエチレングリコール鎖を有するモノマーとし
ては、末端メトキシメタクリレート、末端メトキシアク
リレート、又末端に1つ以上の重合性の官能基を有する
繰り返し単位が2〜15のポリエチレングリコール鎖を
有するモノマーが挙がられる。又、親水性を与える水酸
基を有するモノマーの例としては、2−ヒドロキシエチ
ルメタクリレート、1−ヒドロキシエチルメタクリレー
ト、2−ヒドロキシエチルアクリレート、1−ヒドロキ
シエチルアクリレート、1,2−ジヒドロキシエチルメ
タクリレート、2,2−ジヒドロキシエチルメタクリレ
ート、ビニルアルコール、酢酸ビニル等が挙げられる。
親水性を与えるその他の置換基を有するモノマーの例を
示すと、アクリルアミド、ビニルピロリドン等が挙げら
れるが、これらに限定されるものではない。本発明に用
いられる多孔質フィルターは、繊維からなるものにあっ
ては溶融紡糸法やフラッシュ紡糸法等で好ましく製造さ
れ、更に必要に応じて製造された繊維媒体に圧縮や熱収
縮、任意の液体による処理等の2次的な加工を施し、本
発明で規定する細孔サイズに制御される。又、多孔質体
からなるものは、公知の常圧又は加圧発泡法、押出発泡
法、射出発泡法、等の発泡分解法、溶剤気散法、気体混
入法、化学反応法、溶出法、燒結法等で製造され、その
後上述の繊維の場合と同様、必要に応じて2次加工を施
し、本発明で規定する細孔サイズに制御する。
It is also preferable to impart hydrophilicity to the surface of the porous filter used in the present invention. By imparting hydrophilicity, it works effectively in preventing non-specific adsorption of other cells existing in the treated cell suspension. When making the surface hydrophilic, it is also preferable to introduce a hydroxyl group for the purpose of suppressing adsorption of proteins in cell suspensions such as blood. Further, it is preferable to introduce a cationic group in order to suppress non-specific adsorption because an electrostatic action can be expected. The term "cationic group" as used herein includes amines and amine derivatives and includes tertiary and quaternary amino groups. To impart hydrophilicity to the surface of the porous filter, various functional groups are covalently bonded,
It may be bonded to the surface by ionic bond, hydrophobic bond or the like. As a bonding method, any method such as radiation grafting or coating may be used. Examples of the functional group introduced for imparting hydrophilicity include a polyethylene glycol chain having a repeating unit of 2 to 100, a hydroxyl group, an amide group, an ether group, an ester group and the like. Examples of the monomer having a polyethylene glycol chain that imparts hydrophilicity include a terminal methoxymethacrylate, a terminal methoxyacrylate, and a monomer having a polyethyleneglycol chain having 2 to 15 repeating units having one or more polymerizable functional groups at the terminals. Be done. Examples of the monomer having a hydroxyl group that imparts hydrophilicity include 2-hydroxyethyl methacrylate, 1-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate, 1-hydroxyethyl acrylate, 1,2-dihydroxyethyl methacrylate, and 2,2. -Dihydroxyethyl methacrylate, vinyl alcohol, vinyl acetate and the like can be mentioned.
Examples of the monomer having another substituent that imparts hydrophilicity include, but are not limited to, acrylamide and vinylpyrrolidone. The porous filter used in the present invention is preferably made of a fiber by a melt spinning method, a flash spinning method, or the like, and if necessary, is compressed or heat-shrinked into a produced fiber medium, and any liquid is used. Secondary processing such as treatment by the above is applied to control the pore size defined in the present invention. Further, those made of a porous material include a foaming decomposition method such as a known atmospheric pressure or pressure foaming method, extrusion foaming method, injection foaming method, solvent vaporization method, gas mixing method, chemical reaction method, elution method, It is produced by a sintering method or the like, and thereafter, as in the case of the above-mentioned fiber, secondary processing is performed as necessary to control the pore size defined in the present invention.

【0009】不織布等の繊維状のフィルターを用いる場
合、繊維径が孔径及び細孔分布に寄与する為、その有効
な平均繊維直径を示すことも重要である。本発明の平均
繊維直径の測定は走査電子顕微鏡で繊維状のフィルター
の表面を撮影し、目視により撮影面上に分散している糸
の直径をランダムに100個以上測定して求める。機械
的強度及びモノサイト捕捉性能において有効なフィルタ
ーの繊維直径は10μm以上20μmで、より好ましく
は、12μm以上18μm以下、更に好ましくは13μ
m以上17μm以下である。平均繊維直径が10μm未
満になると他の白血球の直径よりも小さくなる為、非特
異的な吸着性が増大し、選択性が低下する為好ましくな
い。一方20μmを超えるとモノサイドの接触頻度が低
下し除去効率が低くなる為好ましくない。
When a fibrous filter such as a non-woven fabric is used, the fiber diameter contributes to the pore diameter and the pore distribution, so that it is important to show the effective average fiber diameter. The average fiber diameter of the present invention is obtained by photographing the surface of a fibrous filter with a scanning electron microscope and visually measuring 100 or more randomly distributed yarn diameters on the photographed surface. The fiber diameter of the filter effective in mechanical strength and monosite capturing performance is 10 μm or more and 20 μm, more preferably 12 μm or more and 18 μm or less, and further preferably 13 μm.
It is not less than m and not more than 17 μm. If the average fiber diameter is less than 10 μm, it is smaller than the diameters of other white blood cells, so that nonspecific adsorption is increased and the selectivity is decreased, which is not preferable. On the other hand, if it exceeds 20 μm, the contact frequency of monocide is lowered and the removal efficiency is lowered, which is not preferable.

【0010】本発明において多孔質フィルターは細胞浮
遊液の入口及び出口を有する任意の容器に0.05〜
0.5g/cm3 の嵩密度で充填される。0.05g/
cm3未満では十分な大きさの細孔を安定して確保する
ことが難しく、物理的に安定した強度を有するフィルタ
ー装置が実現しにくい。又、0.5g/cm3 を越える
多孔質フィルターでは本発明の要件を満たす細孔を実現
することは難しい。好ましい充填密度は0.1g/cm
3 〜0.4g/cm3 、更に好ましくは0.15g/c
3 〜0.3m3 である。容器の大きさは処理対象細胞
浮遊液の量と処理速度等を考慮して適宜設定する。又、
容器の形状や多孔質フィルターの充填方法に特に限定は
ないが、効率の観点から考えれば、入口から導入された
細胞浮遊液が接触し得る多孔質フィルターの表(おも
て)面の面積(以下、フィルター表面積という)を大き
く確保しつつ同時に容器容積が小さいものが好ましい。
又、単球の捕捉率を考えれば多孔質フィルターの厚みが
薄すぎるものは好ましくない。しかし、細胞浮遊液を連
続的に供給して単球を持続的に高効率で捕捉するために
は、フィルター厚みが大きすぎるのも圧力損失の増大を
招き処理速度を低下させる要因となるので好ましくな
い。フィルターの厚みは、その形状にも依るが、実用的
な範囲として0.1mm〜50mm、好ましくは0.1
mm〜40mmがよく、又、フィルター表面積の実用的
な範囲は製造上の容易さ及び一般的な処理細胞浮遊液量
から考えると0.5cm2 〜300cm2 が良く、小型
化及び操作性から0.5cm2 〜250cm2 、より好
ましくは0.5cm2 〜200cm2 である。
In the present invention, the porous filter is used in an arbitrary container having an inlet and an outlet for cell suspension, and the amount of 0.05 to
It is filled with a bulk density of 0.5 g / cm 3 . 0.05 g /
If it is less than 3 cm 3 , it is difficult to stably secure sufficiently large pores, and it is difficult to realize a filter device having physically stable strength. Further, it is difficult to realize pores satisfying the requirements of the present invention with a porous filter having a weight of more than 0.5 g / cm 3 . Preferred packing density is 0.1 g / cm
3 to 0.4 g / cm 3 , more preferably 0.15 g / c
m 3 is a ~0.3m 3. The size of the container is appropriately set in consideration of the amount of cell suspension to be treated, the treatment speed, and the like. or,
The shape of the container and the method of filling the porous filter are not particularly limited, but from the viewpoint of efficiency, the area of the surface (front) surface of the porous filter with which the cell suspension introduced from the inlet can come into contact ( Hereinafter, it is preferable that the container volume be small while at the same time ensuring a large filter surface area).
Also, considering the capture rate of monocytes, it is not preferable that the thickness of the porous filter is too thin. However, in order to continuously supply the cell suspension liquid and continuously capture the monocytes with high efficiency, an excessively large filter thickness also causes an increase in pressure loss and causes a decrease in processing speed, which is preferable. Absent. The thickness of the filter depends on its shape, but is in a practical range of 0.1 mm to 50 mm, preferably 0.1 mm.
mm~40mm C., also from a practical range Considering the ease and general processing cell suspension volume of production well 0.5cm 2 ~300cm 2, miniaturization and operability of the filter surface area 0 .5cm 2 ~250cm 2, more preferably 0.5cm 2 ~200cm 2.

【0011】本発明の装置の最も単純な装置構造として
は、例えば、特開昭62−243561号公報の図1に
示すように、円筒状の容器の両端に細胞浮遊液の入口、
出口ノズルを設け、その中にマカロニ状、即ち芯部が中
空の円筒状多孔質フィルターを装填して、細胞浮遊液を
該多孔質フィルターの外周面側から供給し内周面側に処
理済み細胞浮遊液を回収してそれを容器外に出口ノズル
を経て導出させる形のものが挙げられる。この場合、多
孔質フィルターは薄い不織布シートからなるものを多重
に巻いてマカロニ状にしたものでも良いし、マカロニ状
に繊維又は多孔質体を充填又は成形したものでも良い。
或は比表面積を高くするために、シート状のフィルター
を細かいプリーツに加工した後に多重に巻くのも好まし
い。又、処理細胞浮遊液量が少量の場合には、例えば、
特開昭59−48173号公報の図2に示すように、デ
ィスク状の容器にシート状のフィルターを挟んだ状態で
充填しフィルターを介して対向する位置に細胞浮遊液の
入口、出口がそれぞれ設けられた装置構造も好適に用い
られる。ディスク状装置の場合はフィルターの表(おも
て)面積(Scm2 )に比べてフィルターを含む容器内
側厚み(Dcm)が薄いものが好ましく、S/D比は1
0〜500cmが好ましい。又、ディスクの形状は円
形、多角形等が好適例であるが、液の出口に向かって錘
状に先細りとなる形状も良い。
The simplest device structure of the device of the present invention is, for example, as shown in FIG. 1 of JP-A-62-243561, an inlet of a cell suspension liquid at both ends of a cylindrical container,
An outlet nozzle is provided, and a macaroni-shaped, that is, a cylindrical porous filter having a hollow core is loaded into the outlet nozzle, and a cell suspension is supplied from the outer peripheral surface side of the porous filter to the inner peripheral surface side of the treated cells. There is a form in which the floating liquid is collected and discharged out of the container through an outlet nozzle. In this case, the porous filter may be a macaroni-shaped product obtained by winding a thin non-woven fabric sheet in multiple layers, or may be a macaroni-shaped product filled or molded with fibers or a porous body.
Alternatively, in order to increase the specific surface area, it is also preferable that the sheet-shaped filter is processed into fine pleats and then wound in multiple layers. If the amount of treated cell suspension is small, for example,
As shown in FIG. 2 of JP-A-59-48173, an inlet and an outlet of a cell suspension are provided at positions facing each other through a filter filled in a disc-shaped container with a sheet-shaped filter interposed therebetween. The device structure described above is also preferably used. In the case of a disk-shaped device, it is preferable that the inside thickness (Dcm) of the container including the filter is smaller than the front surface area (Scm 2 ) of the filter, and the S / D ratio is 1
0-500 cm is preferable. Further, the shape of the disk is preferably a circular shape, a polygonal shape, or the like, but a shape that tapers in a cone shape toward the liquid outlet may be used.

【0012】又本発明の単球及び/又はマクロファージ
選択除去フィルター装置は、多孔質フィルターの上流部
に該多孔質フィルターよりも目の粗い別のフィルターを
積層してもよい。或いは、多孔質フィルター自体が実質
的に平均細孔断面積が連続的又は段階的に減少する構造
であるものでもよい。このような平均細孔断面積が連続
的又は段階的に減少する構造は、平均細孔断面積の異な
る複数のフィルターを積層してなるものでも、或いは予
め平均細孔断面積が連続的に減少するように成形されて
いるものでもよい。具体的には、入口側の平均細孔断面
積250〜500μm2 であり、出口側のそれが100
〜300μm2 である多孔質フィルターが好適に用いら
れる。更に本発明の単球及び/又はマクロファージ選択
除去フィルター装置においては、被処理対象細胞浮遊液
によっては、多孔質フィルターの上流にマイクロアグリ
ゲート等による多孔質フィルターの目詰まりを防ぐた
め、平均細孔断面積が500〜5000μm2 のプレフ
ィルターを設けることもできる。本発明の単球及び/又
はマクロファージ選択除去フィルター装置はオートクレ
ーブ等の熱滅菌、エチレンオキサイドガス滅菌、γ線滅
菌、電子線滅菌等の放射線滅菌、紫外線滅菌など、公知
の任意の方法によって滅菌された後に実用に供せられ
る。
In the monocyte and / or macrophage selective removal filter device of the present invention, another filter having a coarser mesh than the porous filter may be laminated on the upstream portion of the porous filter. Alternatively, the porous filter itself may have a structure in which the average pore cross-sectional area is substantially continuously or stepwise reduced. Such a structure in which the average pore cross-sectional area continuously or gradually decreases can be formed by laminating a plurality of filters having different average pore cross-sectional areas, or the average pore cross-sectional area can be continuously reduced in advance. It may be molded so as to Specifically, the average pore cross-sectional area on the inlet side is 250 to 500 μm 2 and that on the outlet side is 100
A porous filter having a particle size of 300 μm 2 is preferably used. Further, in the monocyte and / or macrophage selective removal filter device of the present invention, depending on the cell suspension to be treated, in order to prevent clogging of the porous filter upstream of the porous filter due to microaggregates, etc. A prefilter having a cross-sectional area of 500 to 5000 μm 2 can also be provided. The monocyte and / or macrophage selective removal filter device of the present invention has been sterilized by any known method such as heat sterilization such as autoclave, ethylene oxide gas sterilization, γ-ray sterilization, radiation sterilization such as electron beam sterilization, and ultraviolet sterilization. It will be put to practical use later.

【0013】[0013]

【実施例】以下に、具体例を挙げて本発明を詳細に説明
する。
The present invention will be described in detail below with reference to specific examples.

【実施例1】ポリエチレンテレフタレートからなる不織
布(平均繊維直径12μm、平均細1断面積265μm
2 、嵩密度0.2g/cm3 )シートをフィルター部厚
みが1.8cmになるように中空円筒状に巻き、これを
両端に液体の入口及び出口を有する2.0cmφ×15
cmの中空状容器に充填した。フィルターの最内周部と
最外周部にはメッシュ状の支持体を設けてフィルター部
を固定した。遠心分離器及び比重遠心法により分離、採
取した単核球浮遊液を、カルシウムイオン、マグネシウ
ムイオン不含HBSSにより希釈し、1.0×108
/20mlに調整した。この単核球浮遊液を検体として
用いた。この単核球浮遊液20mlをペリスタポンプを
用いて流速5ml/分で上記フィルター装置の入口側に
送液して装置出口から処理後の液を回収した。装置に導
入する前と後の単球数は公知のフローサイトメトリー法
で、抗CD14抗体を標識として測定した。この時の単
球除去率は98.1%であった。この時の他の細胞の除
去率は、CD3陽性細胞が30%、CD34陽性細胞が
50%であった。
Example 1 Nonwoven fabric made of polyethylene terephthalate (average fiber diameter 12 μm, average fine 1 cross-sectional area 265 μm
2. Bulk density of 0.2 g / cm 3 ) A sheet is wound into a hollow cylinder so that the thickness of the filter portion is 1.8 cm, and 2.0 cmφ × 15 having a liquid inlet and outlet at both ends.
cm into a hollow container. A mesh-shaped support was provided at the innermost and outermost portions of the filter to fix the filter portion. The mononuclear cell suspension separated and collected by a centrifuge and a specific gravity centrifugation method was diluted with calcium ion- and magnesium ion-free HBSS and adjusted to 1.0 × 10 8 cells / 20 ml. This mononuclear cell suspension was used as a sample. 20 ml of this mononuclear cell suspension was sent to the inlet side of the filter device using a peristaltic pump at a flow rate of 5 ml / min, and the treated liquid was recovered from the outlet of the device. The number of monocytes before and after introduction into the device was measured by a known flow cytometry method using anti-CD14 antibody as a label. At this time, the monocyte removal rate was 98.1%. The removal rate of other cells at this time was 30% for CD3 positive cells and 50% for CD34 positive cells.

【0014】[0014]

【比較例1】ポリエチレンテレフタレートからなる不織
布(平均繊維直径42μm、平均細孔断面積620μm
2 、嵩密度0.2g/cm3 )シートを実施例1と同様
のフィルター装置に組み立てた。実施例1と同様の被処
理液単核球浮遊液を20ml、ペリスタポンプを用いて
流速5ml/分で上記フィルター装置の入口側に送液し
て装置出口から処理後の液を回収した。装置に導入する
前と後の単球数は公知のフローサイトメトリー法で、抗
CD14抗体を標識として測定した。この時の単球除去
率は23.2%であった。この時の他の細胞の除去率
は、CD3陽性細胞が10%、CD34陽性細胞が5%
であった。
Comparative Example 1 Nonwoven fabric made of polyethylene terephthalate (average fiber diameter 42 μm, average pore cross-sectional area 620 μm
2. A sheet having a bulk density of 0.2 g / cm 3 ) was assembled in the same filter device as in Example 1. 20 ml of the liquid to be treated mononuclear cell suspension similar to that in Example 1 was sent to the inlet side of the filter device using a peristaltic pump at a flow rate of 5 ml / min, and the treated liquid was recovered from the outlet of the device. The number of monocytes before and after introduction into the device was measured by a known flow cytometry method using anti-CD14 antibody as a label. The monocyte removal rate at this time was 23.2%. The removal rate of other cells at this time was 10% for CD3 positive cells and 5% for CD34 positive cells.
Met.

【0015】[0015]

【実施例2】ポリエチレンテレフタレートからなる不織
布(平均繊維直径19μm、平均細孔断面積326μm
2 、嵩密度0.2g/cm3 )シートをフィルター部厚
みが1.8cmになるように中空円筒状に巻き、これを
両端に液体の入口及び出口を有する2.0cmφ×5c
mの中空状容器に充填した。フィルターの最内周部と最
外周部にはメッシュ状の支持体を設けてフィルター部を
固定した。遠心分離器及び比重遠心法により分離、採取
した単核球浮遊液を、カルシウムイオン、マグネシウム
イオン不含HBSSにより希釈し、1.5×108 個/
20mlに調整した。この単核球浮遊液を検体として用
いた。この単核球浮遊液20mlをペリスタポンプを用
いて流速5ml/分で上記フィルター装置の入口側に送
液して装置出口から処理後の液を回収した。装置に導入
する前と後の単球数は公知のフローサイトメトリー法
で、抗CD14抗体を標識として測定した。この時の単
球除去率は89.2%であった。この時の他の細胞の除
去率は、CD3陽性細胞が20%、CD34陽性細胞が
20%であった。
Example 2 Nonwoven fabric made of polyethylene terephthalate (average fiber diameter 19 μm, average pore cross-sectional area 326 μm
2 , bulk density 0.2 g / cm 3 ) A sheet is wound into a hollow cylinder so that the thickness of the filter portion is 1.8 cm, and 2.0 cmφ × 5c having a liquid inlet and outlet at both ends.
m hollow container. A mesh-shaped support was provided at the innermost and outermost portions of the filter to fix the filter portion. The mononuclear cell suspension separated and collected by a centrifuge and a specific gravity centrifugation method was diluted with calcium ion- and magnesium ion-free HBSS to obtain 1.5 × 10 8 cells /
Adjusted to 20 ml. This mononuclear cell suspension was used as a sample. 20 ml of this mononuclear cell suspension was sent to the inlet side of the filter device using a peristaltic pump at a flow rate of 5 ml / min, and the treated liquid was recovered from the outlet of the device. The number of monocytes before and after introduction into the device was measured by a known flow cytometry method using anti-CD14 antibody as a label. At this time, the monocyte removal rate was 89.2%. At this time, the removal rate of other cells was 20% for CD3 positive cells and 20% for CD34 positive cells.

【0016】[0016]

【実施例3】ポリエチレンテレフタレートからなる不織
布(平均繊維直径12μm、平均細孔断面積265μm
2 、嵩密度0.1g/cm3 )シートをフィルター部厚
みが3.3cmになるように中空円筒状に巻き、更にそ
の外側にポリエチレンテレフタレートからなる別の不織
布(平均繊維直径19μm、平均細孔断面積326μm
2 、嵩密度0.1g/cm3 )シートをフィルター部厚
みが3.0cmになるように巻きつけたフィルター材
を、両端に液体の入口及び出口を有する6.5cmφ×
15cmの円筒状容器に充填した。フィルターの最内周
部と最外周部にはメッシュ状の支持体を設けてフィルタ
ー部を固定した。ACD−A液を8:1の比で加えた牛
血液2000mlを、ペリスタポンプを用いて流速5m
l/分で上記フィルター装置の入口側に送液して装置出
口から処理後の液を回収した。白血球の回収率は70%
であった。このときの白血球分画は、公知のメイギムザ
細胞染色法で染色し、細胞を100個識別し、フィルタ
ー装置カラム前後の細胞分率と白血球の回収率よりそれ
ぞれの細胞の回収率を求めた。この時の単球除去率は7
5.1%であった。また、他の細胞の除去率は、リンパ
球25%、顆粒球35%であった。
Example 3 Nonwoven fabric made of polyethylene terephthalate (average fiber diameter 12 μm, average pore cross-sectional area 265 μm
2 , a sheet having a bulk density of 0.1 g / cm 3 ) is wound into a hollow cylindrical shape so that the thickness of the filter portion is 3.3 cm, and another non-woven fabric made of polyethylene terephthalate is provided on the outside thereof (average fiber diameter 19 μm, average pores). Cross-sectional area 326 μm
2 , bulk density 0.1 g / cm 3 ) A filter material obtained by winding a sheet so that the filter portion thickness becomes 3.0 cm, and has a liquid inlet and outlet at both ends of 6.5 cmφ ×
A 15 cm cylindrical container was filled. A mesh-shaped support was provided at the innermost and outermost portions of the filter to fix the filter portion. 2000 ml of bovine blood to which ACD-A solution was added at a ratio of 8: 1 was used to flow 5 m with a peristaltic pump.
The solution was sent to the inlet side of the filter device at 1 / min, and the treated liquid was recovered from the outlet of the device. White blood cell recovery rate is 70%
Met. The leukocyte fraction at this time was stained by the known May-Giemsa cell staining method to identify 100 cells, and the recovery rate of each cell was determined from the cell ratio before and after the filter device column and the recovery rate of leukocytes. The monocyte removal rate at this time is 7
It was 5.1%. The removal rate of other cells was 25% for lymphocytes and 35% for granulocytes.

【0017】[0017]

【比較例2】ポリエチレンテレフタレートからなる不織
布(平均繊維直径2.3μm、平均細孔断面積1.8μ
2 、嵩密度0.1g/cm3 )シートをフィルター部
厚みが3.3cmになるように中空円筒状に巻き、更に
その外側にポリエチレンテレフタレートからなる別の不
織布(平均繊維直径19μm、平均細孔断面積326μ
2 、嵩密度0.1g/cm3 )シートをフィルター部
厚みが3.0cmになるように巻きつけたフィルター材
を、両端に液体の入口及び出口を有する6.5cmφ×
15cmの円筒状容器に充填した。フィルターの最内周
部と最外周部にはメッシュ状の支持体を設けてフィルタ
ー部を固定した。実施例3と同様の被処理液を、ペリス
タポンプを用いて流速5ml/分で上記フィルター装置
の入口側に送液して装置出口から処理後の液を回収し
た。白血球の回収率は10%、単球除去率は95.1%
であった。また、他の細胞の回収率は、リンパ球83
%、顆粒球95%であった。
Comparative Example 2 Nonwoven fabric made of polyethylene terephthalate (average fiber diameter 2.3 μm, average pore cross-sectional area 1.8 μm
m 2 and bulk density 0.1 g / cm 3 ) A sheet was wound into a hollow cylindrical shape so that the thickness of the filter portion was 3.3 cm, and another non-woven fabric (average fiber diameter 19 μm, average fineness) made of polyethylene terephthalate was wound on the outside thereof. Hole cross-sectional area 326μ
m 2 and bulk density 0.1 g / cm 3 ) A filter material obtained by winding a sheet so that the thickness of the filter portion becomes 3.0 cm, and has a liquid inlet and an outlet at both ends of 6.5 cmφ ×
A 15 cm cylindrical container was filled. A mesh-shaped support was provided at the innermost and outermost portions of the filter to fix the filter portion. The same liquid to be treated as in Example 3 was sent to the inlet side of the filter device using a peristaltic pump at a flow rate of 5 ml / min, and the treated liquid was recovered from the outlet of the device. Leukocyte recovery rate is 10%, monocyte removal rate is 95.1%
Met. In addition, the recovery rate of other cells was 83%
% And granulocytes 95%.

【0018】[0018]

【実施例4】ポリエチレンテレフタレートからなる不織
布(平均繊維直径15μm、平均細孔断面積350μm
2 、嵩密度0.1g/cm3 )シートをフィルター部厚
みが1.5cmになるように対向位置に液の入口、出口
を有する4.5cm×4.5cmの四角形の扁平容器に
充填した。ACD−A液を8:1の比で加えた牛血液2
0mlを、ペリスタポンプを用いて流速5ml/分で上
記フィルター装置の入口側に送液して装置出口から処理
後の液を回収した。白血球の回収率は70%であった。
このときの白血球分画は、公知のメイギムザ細胞染色法
で染色し、細胞を100個識別し、フィルター装置カラ
ム前後の細胞分率と白血球の回収率よりそれぞれの細胞
の回収率を求めた。この時の単球除去率は77.1%で
あった。また、他の細胞の除去率は、リンパ球21%、
顆粒球41%であった。
Example 4 Nonwoven fabric made of polyethylene terephthalate (average fiber diameter 15 μm, average pore cross-sectional area 350 μm
2. Bulk density of 0.1 g / cm 3 ) The sheet was filled in a 4.5 cm × 4.5 cm rectangular flat container having a liquid inlet and an outlet at opposite positions so that the thickness of the filter portion was 1.5 cm. Bovine blood 2 to which ACD-A solution was added at a ratio of 8: 1
0 ml was sent to the inlet side of the filter device using a peristaltic pump at a flow rate of 5 ml / min, and the treated liquid was recovered from the outlet of the device. The recovery rate of white blood cells was 70%.
The leukocyte fraction at this time was stained by the known May-Giemsa cell staining method to identify 100 cells, and the recovery rate of each cell was determined from the cell ratio before and after the filter device column and the recovery rate of leukocytes. At this time, the monocyte removal rate was 77.1%. The removal rate of other cells was 21% for lymphocytes,
It was 41% of granulocytes.

【0019】[0019]

【比較例3】ポリエチレンテレフタレートからなる不織
布(平均繊維直径40μm、平均細孔断面積3162μ
2 、嵩密度0.1g/cm3 )シートを用いて実施例
4と同様のフィルター装置を作製した。ACD−A液を
8:1の比で加えた牛血液20mlを、ペリスタポンプ
を用いて流速5ml/分で上記フィルター装置の入口側
に送液して装置出口から処理後の液を回収した。白血球
の回収率は95%であった。このときの白血球分画は、
公知のメイギムザ細胞染色法で染色し、細胞を100個
識別し、フィルター装置カラム前後の細胞分率と白血球
の回収率よりそれぞれの細胞の回収率を求めた。この時
の単球除去率は5%であった。また、他の細胞の回収率
は、リンパ球90%、顆粒球96%であった。
Comparative Example 3 Nonwoven fabric made of polyethylene terephthalate (average fiber diameter 40 μm, average pore cross-sectional area 3162 μ
A filter device similar to that in Example 4 was produced using a sheet having m 2 and bulk density of 0.1 g / cm 3 ). 20 ml of bovine blood to which the ACD-A solution was added at a ratio of 8: 1 was sent to the inlet side of the filter device using a peristaltic pump at a flow rate of 5 ml / min, and the treated solution was recovered from the outlet of the device. The recovery rate of white blood cells was 95%. The white blood cell fraction at this time is
The cells were stained by a known May-Giemsa cell staining method, 100 cells were identified, and the recovery rate of each cell was determined from the cell ratio before and after the filter device column and the recovery rate of leukocytes. The monocyte removal rate at this time was 5%. The recovery rate of other cells was 90% for lymphocytes and 96% for granulocytes.

【0020】[0020]

【発明の効果】本発明の単球及び/又はマクロファージ
選択除去フィルター装置は、末梢血幹細胞移植時の単球
除去用、骨髄移植時の単球除去用、輸血用及び炎症性疾
患患者血からの単球の除去等に好適であり、単に被処理
細胞浮遊液を該装置に通すのみの極めて簡単な操作で単
球が優先的に除去される。
INDUSTRIAL APPLICABILITY The filter device for selective removal of monocytes and / or macrophages of the present invention is for removing monocytes at the time of peripheral blood stem cell transplantation, for removing monocytes at the time of bone marrow transplantation, for blood transfusion and from blood of patients with inflammatory diseases. It is suitable for removal of monocytes and the like, and monocytes are preferentially removed by an extremely simple operation of simply passing the treated cell suspension through the device.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 平均細孔断面積が100μm2 〜500
μm2 である多孔質フィルターを、液体の入口及び出口
を有する容器に0.05g/cm3 〜0.5g/cm3
の嵩密度で充填したことを特徴とする、細胞浮遊液中の
単球及び/又は単球由来のマクロファージ選択除去フィ
ルター装置。
1. The average pore cross-sectional area is 100 μm 2 to 500.
A porous filter having a diameter of μm 2 is added to a container having an inlet and an outlet for liquid in an amount of 0.05 g / cm 3 to 0.5 g / cm 3.
A device for selective removal of monocytes in a cell suspension and / or macrophage-derived macrophages in a cell suspension, the device being filled with the bulk density of 1.
【請求項2】 多孔質フィルターが平均繊維径10μm
〜20μmの不織布からなる請求項1記載の細胞浮遊液
中の単球及び/又は単球由来のマクロファージ選択除去
フィルター装置。
2. The porous filter has an average fiber diameter of 10 μm.
The filter device for selective removal of monocytes and / or monocyte-derived macrophages in a cell suspension according to claim 1, which is composed of a non-woven fabric of about 20 μm.
JP25720195A 1995-09-11 1995-09-11 Monocyte and / or monocyte-derived macrophage selective removal filter device Expired - Fee Related JP3812909B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP25720195A JP3812909B2 (en) 1995-09-11 1995-09-11 Monocyte and / or monocyte-derived macrophage selective removal filter device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25720195A JP3812909B2 (en) 1995-09-11 1995-09-11 Monocyte and / or monocyte-derived macrophage selective removal filter device

Publications (2)

Publication Number Publication Date
JPH0975076A true JPH0975076A (en) 1997-03-25
JP3812909B2 JP3812909B2 (en) 2006-08-23

Family

ID=17303088

Family Applications (1)

Application Number Title Priority Date Filing Date
JP25720195A Expired - Fee Related JP3812909B2 (en) 1995-09-11 1995-09-11 Monocyte and / or monocyte-derived macrophage selective removal filter device

Country Status (1)

Country Link
JP (1) JP3812909B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007051980A (en) * 2005-08-19 2007-03-01 Okayama Univ Graft-versus-host disease testing method, testing reagent, and prophylactic and / or therapeutic screening method
CN102223907A (en) * 2008-11-25 2011-10-19 旭化成可乐丽医疗株式会社 Utilization of antioxidant agent in device for selectively removing hla-dr-positive monocytes and for production of same
WO2012141032A1 (en) * 2011-04-11 2012-10-18 株式会社カネカ Mononuclear cell preparation material and mononuclear cell preparation method using same
WO2022111625A1 (en) * 2020-11-30 2022-06-02 康码(上海)生物科技有限公司 Microporous filter cloth and application thereof in nucleic acid extraction

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007051980A (en) * 2005-08-19 2007-03-01 Okayama Univ Graft-versus-host disease testing method, testing reagent, and prophylactic and / or therapeutic screening method
CN102223907A (en) * 2008-11-25 2011-10-19 旭化成可乐丽医疗株式会社 Utilization of antioxidant agent in device for selectively removing hla-dr-positive monocytes and for production of same
EP2361644A4 (en) * 2008-11-25 2013-02-27 Asahi Kasei Medical Co Ltd Utilization of antioxidant agent in device for selectively removing hla-dr-positive monocytes and for production of same
WO2012141032A1 (en) * 2011-04-11 2012-10-18 株式会社カネカ Mononuclear cell preparation material and mononuclear cell preparation method using same
WO2022111625A1 (en) * 2020-11-30 2022-06-02 康码(上海)生物科技有限公司 Microporous filter cloth and application thereof in nucleic acid extraction

Also Published As

Publication number Publication date
JP3812909B2 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
EP0620017B2 (en) Device and method for depletion of the leukocyte content of blood products
US4923620A (en) Device for depletion of the leukocyte content of blood and blood components
US4925572A (en) Device and method for depletion of the leukocyte content of blood and blood components
EP0329303B1 (en) Device and method for separating leukocytes from platelet concentrate
CN1886498B (en) Tangential flow filtration devices and methods for stem cell enrichment
US4976861A (en) Method for determining the wetting characteristic of a porous medium
JP4138488B2 (en) Body fluid treatment device capable of direct blood perfusion
GB2231282A (en) Blood filter
WO2018194061A1 (en) Filter container for separating cells and filter device for separating cells
JPH05148151A (en) Filter material for removing leukocyte
JP5336109B2 (en) Methods for enriching mononuclear cells and platelets
JP2002526172A (en) Biological fluid filters and systems
JP6143746B2 (en) Nucleated cell capture filter or nucleated cell preparation method using the same
JPH067429A (en) Blood filter medium
JP3812909B2 (en) Monocyte and / or monocyte-derived macrophage selective removal filter device
JP3270125B2 (en) Leukocyte trapping material
JP3250833B2 (en) Leukocyte selective capture filter material
JPH0780062A (en) Endotoxin removing device and production of purified blood
JP3386195B2 (en) Leukocyte selective capture device and leukocyte capture device
JPH119270A (en) Separation and recovery of nucleated cell and separating and recovering device for nucleated cell
JP2019024426A (en) Cell separation device and method of obtaining cell-containing liquid comprising monocytes
JPH10201470A (en) Cell separation and cell floating solution
JPS61253071A (en) Blood purifying apparatus
JP4318234B2 (en) How to induce monocyte differentiation
JP2008079890A (en) Blood component processing material and device

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050811

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060529

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090609

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090609

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090609

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100609

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110609

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110609

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120609

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120609

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130609

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130609

Year of fee payment: 7

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130609

Year of fee payment: 7

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130609

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140609

Year of fee payment: 8

LAPS Cancellation because of no payment of annual fees